PubRank

H L McLeod

Author PubWeight™ 117.30‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008 4.54
2 The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012 2.90
3 The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007 2.18
4 Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996 2.02
5 Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002 1.98
6 Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013 1.94
7 CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 2013 1.77
8 The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999 1.76
9 MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 1.70
10 Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003 1.59
11 Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003 1.59
12 Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000 1.57
13 Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998 1.50
14 Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002 1.49
15 Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999 1.48
16 Laser capture microscopy. Mol Pathol 2000 1.43
17 Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer 1997 1.42
18 A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010 1.35
19 Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999 1.34
20 Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998 1.30
21 Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993 1.29
22 Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001 1.29
23 Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007 1.28
24 Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004 1.27
25 Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000 1.24
26 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 2001 1.24
27 Comparative genomic hybridization and chromosomal instability in solid tumours. Br J Cancer 1999 1.24
28 Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2009 1.22
29 Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999 1.19
30 Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996 1.18
31 Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001 1.18
32 Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007 1.16
33 PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 2007 1.11
34 Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 2001 1.09
35 Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001 1.09
36 Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001 1.08
37 Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 2003 1.08
38 Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 2000 1.08
39 Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 2000 1.08
40 Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 2001 1.07
41 Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors. Cancer Res 1998 1.06
42 Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer 2001 1.05
43 Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 2001 1.04
44 Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer 2001 1.04
45 Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007 1.03
46 Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 2000 1.03
47 Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 2001 1.03
48 Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998 1.02
49 Cancer pharmacogenetics. Br J Cancer 2004 1.01
50 Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res 1999 1.01
51 Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets 2006 1.00
52 Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001 0.99
53 Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 2000 0.99
54 c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002 0.99
55 Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993 0.98
56 Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 2000 0.98
57 Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J 2010 0.97
58 Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br J Cancer 2005 0.96
59 Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 2011 0.94
60 Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genet Cytogenet 2000 0.92
61 Crohn's disease: ethnic variation in CARD15 genotypes. Gut 2003 0.91
62 Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998 0.90
63 Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 1999 0.90
64 CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003 0.89
65 Pharmacogenetics: more than skin deep. Nat Genet 2001 0.89
66 Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 1994 0.89
67 Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant 2003 0.89
68 CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J 2006 0.88
69 Expression of drug pathway proteins is independent of tumour type. J Pathol 2006 0.87
70 Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol 2000 0.87
71 CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000 0.86
72 Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer. Cancer Res 2000 0.85
73 Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. Int J Oncol 2000 0.85
74 Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol 2003 0.85
75 Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Hum Mutat 2000 0.85
76 Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide. Mol Pathol 1997 0.84
77 Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J 2009 0.84
78 Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. Int J Cancer 2001 0.84
79 Pharmacogenetics in rheumatology: the prospects and limitations of an emerging field. Rheumatology (Oxford) 2002 0.84
80 Interethnic variability in human drug responses. Drug Metab Dispos 2001 0.83
81 Ready when you are: easing into preemptive pharmacogenetics. Clin Pharmacol Ther 2012 0.83
82 Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 1999 0.82
83 Analysis of uracil DNA glycosylase in human colorectal cancer. Int J Oncol 2001 0.82
84 Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br J Cancer 2001 0.82
85 Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol 2000 0.82
86 High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 1994 0.82
87 Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin Pharmacol Ther 2008 0.81
88 Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer 2005 0.81
89 Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 2007 0.80
90 PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication? Clin Pharmacol Ther 2011 0.80
91 The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa. J Mol Evol 2001 0.80
92 Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics J 2005 0.79
93 Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun 2000 0.79
94 RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. Br J Cancer 2004 0.78
95 Modelling cortical cataractogenesis. XI. Vitamin C reduces gamma-crystallin leakage from lenses in diabetic rats. Exp Eye Res 1990 0.78
96 Relationship between loudness discomfort level and acoustic reflex threshold for normal and sensorineural hearing-impaired individuals. J Speech Hear Res 1979 0.78
97 Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer. Pharmacotherapy 1997 0.78
98 A clinical trial of antihistamine, decongestant, or placebo in antibiotic-treated acute otitis media followed with pneumatic otoscopy and impedance tympanometry. Mil Med 1981 0.78
99 Now's the time to find biomarkers on purpose. Ann Oncol 2010 0.77
100 EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose. Ann Oncol 2008 0.77
101 Modelling cortical cataractogenesis VIII: effects of butylated hydroxytoluene (BHT) in reducing protein leakage from lenses in diabetic rats. Exp Eye Res 1986 0.76
102 Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol 2008 0.75
103 Commentary on interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity. Eur J Clin Pharmacol 1995 0.75
104 Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. Public Health Genomics 2014 0.75
105 Pharmacokinetic differences between ethnic groups. Lancet 2002 0.75
106 Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy? Ann Oncol 2000 0.75
107 Concordance of phenotype and genotype for CYP2D6. Clin Pharmacol Ther 1994 0.75
108 Metabolism of azathioprine. Transplantation 1996 0.75
109 Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides Nucleotides Nucleic Acids 2004 0.75
110 Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR. Nucleosides Nucleotides Nucleic Acids 2004 0.75
111 Race and responsiveness to drugs for heart failure. N Engl J Med 2001 0.75
112 High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. J Chromatogr B Biomed Sci Appl 1997 0.75
113 Modelling cortical cataractogenesis. XII: Supplemental vitamin A treatment reduces gamma-crystallin leakage from lenses in diabetic rats. Lens Eye Toxic Res 1992 0.75
114 Found in translation: annals of oncology and translational research. Ann Oncol 2011 0.75
115 Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse. Pharmacology 1998 0.75